Fulgent Genetics (FLGT) & Its Peers Critical Comparison

Fulgent Genetics (NASDAQ:FLGT – Get Free Report) is one of 233 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it contrast to its peers? We will compare Fulgent Genetics to related businesses based on the strength of its risk, valuation, institutional ownership, analyst recommendations, dividends, profitability and earnings.

Institutional and Insider Ownership

48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 36.2% of Fulgent Genetics shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Providers & Services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Fulgent Genetics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fulgent Genetics -27.53% -5.66% -5.16%
Fulgent Genetics Competitors -1.05% -139.10% -2.48%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Fulgent Genetics and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fulgent Genetics 1 2 0 0 1.67
Fulgent Genetics Competitors 1890 7763 13430 841 2.55

Fulgent Genetics currently has a consensus target price of $25.00, suggesting a potential upside of 3.65%. As a group, “Healthcare Providers & Services” companies have a potential upside of 21.99%. Given Fulgent Genetics’ peers stronger consensus rating and higher possible upside, analysts plainly believe Fulgent Genetics has less favorable growth aspects than its peers.

Risk & Volatility

Fulgent Genetics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Fulgent Genetics’ peers have a beta of 0.98, meaning that their average share price is 2% less volatile than the S&P 500.

Earnings and Valuation

This table compares Fulgent Genetics and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Fulgent Genetics $322.67 million -$60.51 million -7.81
Fulgent Genetics Competitors $21.28 billion $301.67 million -3.54

Fulgent Genetics’ peers have higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Fulgent Genetics peers beat Fulgent Genetics on 10 of the 13 factors compared.

About Fulgent Genetics

(Get Free Report)

Fulgent Genetics, Inc. is a diagnostics and therapeutics company that provides genetic testing and other laboratory services. Its offerings include tests for inherited conditions, cancer and infectious diseases, as well as pathology services for healthcare providers and health systems. Founded in 2011 and headquartered in Temple City, California, the company expanded its diagnostic capabilities through its 2021 acquisition of Inform Diagnostics, a provider of specialized pathology services. Fulgent also conducts research and development focused on precision therapies, including potential cancer treatments.

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.